As LMO2 expression is an independent poor prognostic factor in DLBCL treated with the R-CHOP regimen (155), there is a rationale for the evaluation of PARP inhibition in combination with chemo-immunotherapy in LMO2-expressing DLBCL. Here, PARP1 is linked to diffuse large B-cell lymphoma.